linjc16/ctgov huggingface dataset:
Social Cognitive Training for Psychosis: Treatment Development

Study Overview
=================
Brief Summary
-----------------
The primary aim of this proposal is to develop, refine, manualize and assess the feasibility and preliminary efficacy of a brief, narrowly-focused social cognitive intervention for individuals with psychosis. The intervention will focus on helping individuals interpret social situations, specifically the intentions and feelings of others. Study methods include preliminary treatment and manual development based on series of uncontrolled cases, manual refinement, and a small feasibility/efficacy trial of the newly developed intervention.

Official Title
-----------------
Social Cognitive Training for Psychosis: Phase I Treatment Development

Conditions
-----------------
Schizophrenia, Psychosis

Intervention / Treatment
-----------------
* Behavioral: social cognitive training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of schizophrenia or other psychotic disorder Age between 18 and 55 Psychiatrically stable Clinician agrees to individual's participation in study English as primary language Exclusion Criteria: current (past 30 days) symptoms of alcohol abuse/dependence developmental disability severe auditory/visual impairment or known neurological disorder participant has a legal conservator

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: social cognitive training<br> | Behavioral: social cognitive training<br>* social cognitive training, 8-10 sessions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| social cognition | AIHQ Eyes Task Hinting Task IPSAQ | change from baseline to approximately 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
schizophrenia, treatment, social cognition
Oxytocin Administration and Emotion Recognition Abilities in Adults Reporting Adverse Childhood Experiences

Study Overview
=================
Brief Summary
-----------------
This study evaluates whether intranasal administration of a single dose of oxytocin improves the ability to recognize emotional states. In a cross-over design, half of the participants first received oxytocin, the other half first received placebo.

Detailed Description
-----------------
Adverse childhood experience such as neglect or abuse can lead to long-term deficits in emotion processing abilities, and these effects might be mediated via alterations in oxytocin production or sensitivity. The goal of this study was to test whether emotion recognition abilities and empathy might be improved by intranasal oxytocin administration in adults with a history of childhood maltreatment. In a double-blind, placebo-controlled experiment with a crossover design, we assessed the performance of 40 healthy participants with a history of childhood adversity on the Reading the Mind in the Eyes Test (RMET) and an emotion recognition task under 24 IU oxytocin vs. placebo and compared them to a control group of 40 matched individuals without traumatic childhood experiences.

Official Title
-----------------
Long-term Consequences of Childhood Adversity: Exploring Stress Responsive Molecular Pathways and Psychobiological Intervention Models

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Oxytocin
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • presence of moderate to severe experiences of childhood adversity (early adversity group) Exclusion Criteria: Acute psychiatric disorders and personality disorders or psychiatric disorders within the last 12 months Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Oxytocin<br>Single dose of intranasally administered 24 IU of Oxytocin (Syntocinon-Spray Novartis, Switzerland) | Drug: Oxytocin<br> <br> * Other names: Syntocinon;|
| Placebo Comparator: Placebo<br>All ingredients except for oxytocin. | Other: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reading the Mind in the Eyes Test | Requires participants to infer complex mental states fromthe eye region | 45 minutes post-dose | 
| Gradual Emotion Recognition Test | Requires participants to swiftly and accurately detect basic emotions form naturalistic, animated stimuli. | 50 minutes post-dose |
Diethylhomospermine (DEHSPM) for Refractory AIDS-Related Diarrhea

Study Overview
=================
Brief Summary
-----------------
To perform preliminary clinical testing of diethylhomospermine (DEHSPM), a polyamine analogue, for refractory AIDS-related diarrhea. Possibly, DEHSPM will reduce stool volume and frequency in patients with refractory AIDS-related diarrhea.

Detailed Description
-----------------
Possibly, DEHSPM will reduce stool volume and frequency in patients with refractory AIDS-related diarrhea. Patients are initially hydrated for 24 hours, followed by a 3-day baseline period. They then receive intravenous infusions of DEHSPM three times per day for 3 days, followed by observation for 3 days.

Official Title
-----------------
Diethylhomospermine (DEHSPM) for Refractory AIDS-Related Diarrhea

Conditions
-----------------
Diarrhea, HIV Infections

Intervention / Treatment
-----------------
* Drug: Diethylhomospermine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have: ARC or AIDS by CDC criteria. Uncontrolled diarrhea unresponsive to high-dose, nonspecific antidiarrheal therapy. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Known idiopathic ulcerative colitis or Crohn colitis. Acute stool-culture-positive bacterial colitis. Acute amoebic colitis. Pseudomembranous colitis with Clostridium difficile toxin positivity. Short-gut syndrome. Chronic pancreatitis. Ischemic bowel disease. Enteroenteric fistulae. Other gastrointestinal tract disorders known to cause diarrhea. Underlying evidence of immunosuppression other than that related to HIV infection. Unable or unwilling to have subcutaneous injections. Clinically significant CNS, hepatic, or renal disease. Concurrent Medication: Excluded: Other experimental antidiarrheal drugs. Antibiotic therapy. Prior Medication: Excluded: Other experimental drugs within 1 month prior to study entry. Required: At least 2 weeks of prior high-dose, nonspecific antidiarrheal therapy (i.e., loperamide, diphenoxylate hydrochloride-atropine sulfate, or opiates) at maximally tolerable doses.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Diethylhomospermine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Antidiarrheals, Diarrhea, Acquired Immunodeficiency Syndrome, AIDS-Related Complex, N(1),N(14)-bis(ethyl)homospermine
Temperature Variation During Meditative Practices

Study Overview
=================
Brief Summary
-----------------
The temperature on selected points of the hands has been monitored during meditative practices. The practitioner is in complete rest for the time of the measure, and only mental activity is carried out. The purpose is to verify if the heat sensation, that is normally felt, is a real, measurable physiological effect, or if it is just a subjective feeling. Quantitative data analysis is foreseen.

Detailed Description
-----------------
Qigong is a traditional Chinese method for wellness and healing. During practice, which is based on the Qi circulation, it is usual to feel warmth, especially at the hands. The main purpose of this study is to verify if the sensation of heat is not just a subjective feeling but is a real, measurable physiological effect. Quantitative information will be hopefully derived from a simple data analysis. The study will be extended also to deep prayer meditation. The measurement sessions will consist of two periods of practice separated by one pause period, to ensure that the temperature variation is not due to spurious effects. T type thermocouples will be used for the temperature measurements, with sensors in the form of small copper disk. The thermocouples will be connected to a data logger, and the results analyzed. The sensors will be positioned in different points of the hands, either on the palm and on the dorsum. The Laogong (PC8) acupuncture point will be preferentially chosen, because is a very important point, from the energetic point of view, of the Traditional Chinese Medicine. and because the sensation of heat is more acute in this point. Other points will be also measured, and compared with the Laogong.

Official Title
-----------------
Studies of Physiological Effects During Practices of Alternative Mediicine

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: . Experience in meditative practice Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Temperature variation during meditative practice | The variation of the temperature in specific points of the hands will be obtained during meditative practice. In general the study will consist in two periods of practice separated by a pause | 1 hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of temperature variation in different points of the hands | The temperature will be measured in different points of the hands, in relation with relevant points of the Traditional Chines medicine (Acupuncture points), and their behavior compared | 1 hour |
Radiation Oncology Mobile Application

Study Overview
=================
Brief Summary
-----------------
To develop a novel a mobile phone application (available on Android and IOS) for patients receiving radiation treatment for head and neck cancer. Through this application, patients will get access to their treatment calender, through a system connected with Mosiac database, which provides a timely and precise access to their treatments schedule. In addition, patients will be able to report their treatment related toxicity in real time fashion, these symptoms will be addressed daily instead of the weekly floor clinic checks. Furthermore, the radiation oncologist will receive an instant notification through the application, if there is error in patient's treatment (missing field, wrong dose, etc..)

Official Title
-----------------
Radiation Oncology Mobile Application: Symptoms Reporting System and Quality Assurance Tool

Conditions
-----------------
Head and Neck Cancer, Radiation Toxicity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients receiving definitive or adjuvant RT to head and neck site Chemotherapy is allowed PS:0-1 Has a smart phone Exclusion Criteria: Poor performance early laryngeal cancer Patient with metastatic disease, or palliative intent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| head and neck radiotherapy patients<br>(Single arm); Patients receiving radiotherapy for head and neck cancers can report their symptoms through the mobile app. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Grade of symptoms improved with early intervention. | using CTCAE v.5 | only during RT (7WEEKS) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| compliance on the mobile. | number of reports. | Only during RT (7WEEKS) |
Long-term Outcomes of Patients After Coronary Bifurcation Stenting

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the long-term clinical outcomes after stenting bifurcation coronary artery lesions, and to determine whether simple or more complex techniques are associated with a better clinical outcome. We will also assess the risk factors associated with poorer clinical outcomes

Detailed Description
-----------------
Coronary artery disease affecting the branch points of coronary arteries (bifurcation lesions) has a higher rate of restenosis after angioplasty than disease in regions not involving branch points. Post-procedural angiographic outcomes and in-hospital outcomes have been documented for a variety of techniques, but none have examined the long-term clinical outcomes. Long-term clinical outcomes are important from the patients point of view and also determine the use of resources. Knowledge of the long-term outcomes from the various techniques used to treat bifurcation lesions would be important in determining guidelines for the treatment of bifurcation lesions. If simple techniques offer similar or better outcomes than more complex strategies, then this would justify simpler techniques such as main vessel stenting that would use less resources, expose the patient to less radiation, and contrast related to prolonged angioplasty procedures. Comparisons: We will compare the long-term outcomes of simple versus complex stent techniques, and determine other risk factors for long-term outcome

Official Title
-----------------
Long-term Outcomes of Patients After Coronary Bifurcation Stenting

Conditions
-----------------
Coronary Artery Disease, Death, Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: de novo coronary artery lesion in a main branch with at least a 50% stenosis lesions involve the ostium of a side branch artery main branch and side branch with reference diameters of at least 2mm at least one stent used to treat the lesion Exclusion Criteria: restenosis lesions reference side branch artery less than 2mm diameter multiple bifurcation lesions
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
coronary artery disease, bifurcation lesions, percutaneous interventions, stenting, outcomes, death, myocardial infarction
An Observational Study to Investigate How Patients Experience the Ability to Adjust Their Asthma Maintenance Medication

Study Overview
=================
Brief Summary
-----------------
An observational study to investigate how patients experience the ability to adjust their asthma maintenance medication according to instructions received from their physician. The primary aim is to create an insight in the perception of the patient when he has the ability to adjust his own maintenance treatment and how the patient exercises this in the daily practice.

Official Title
-----------------
An Observational Study to Investigate How Patients Experience the Ability to Adjust Their Asthma Maintenance Medication According to Instructions Received From Their Physician (AMD).

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Inclusion Criteria: patients with prescription of budesonide/formoterol Turbuhaler 200/6 (adjustable maintenance dosing) and whom received instructions from their physician to adjust their asthma maintenance medication.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary aim is to create an insight in the perception of the patient when he has the ability to adjust his own maintenance treatment and how the patient exercises this in the daily practice. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The secondary goal is to investigate the efficacy of the treatment with budesonide/formoterol AMD on the patients asthma control measured with the ACQ. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma Control
Multidetector Raw CT as a Single Tool in the Setting of Ischemic Stroke

Study Overview
=================
Brief Summary
-----------------
This is a prospective study including acute ischemic stroke patients aged 18 to 90. Multidetector raw CT is performed in acute ischemic stroke patients. Heart, neck vessels and brain arteries are studied during the same acquisition. Results are compared with the standard methods including transesophageal echocardiography (TEE), Doppler ultrasound (DUS) and MR angiography (MRA) of neck vessels. The main criteria is the ability of CT to classify the stroke etiology correctly according to the TOAST classification in comparison with the standard methods.

Official Title
-----------------
Evaluation of Multidetector Raw Computerized Tomography in the Etiological Analysis of Acute Ischemic Stroke: the COCASE Protocol.

Conditions
-----------------
Ischemic Stroke

Intervention / Treatment
-----------------
* Device: Multidetector raw CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute (< 1 week) ischemic stroke patient aged 18 to 90 Informed consent obtained Presence of health insurance Exclusion Criteria: Pregnancy or absence of efficient contraceptive method Allergy Allergy to contrast material Asthma Renal failure (blood creatinine > 130 µmoles/l, creatinine clearance < 80 ml/mn according to Cockroft method) Myeloma Hyperthyroidism (uncontrolled) Difficulties to synchronize CT to heart rhythm Contra-indication to TEE or MRI Absence or retirement of informed consent Absence of health insurance

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Multidetector raw CT<br> | Device: Multidetector raw CT<br>* Multidetector raw CT<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ability of CT to classify the stroke etiology correctly (TOAST classification) in comparison to reference methods (MRA, DUS, TEE) |  | classify the stroke etiology | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ability of CT to detect the source of stroke in each etiological group. Reliability of CT in quantitative measures of artery stenosis, aortic atheroma, heart thrombus, heart tumors). Tolerance of CT |  | detect the source of stroke | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Stroke, ischemic, etiology, TOAST, CT, multidetector
Shortening Duration of Antiarrhythmic Medication for SVT in Infants

Study Overview
=================
Brief Summary
-----------------
The infants diagnosed with SVT are treated with antiarrhythmic medication to prevent the recurrence of SVT. This prospective observational cohort study evaluates efficacy and safety of shortening duration of antiarrhythmic medication to four months in infants with SVT. Primary outcome is incidence of recurrent SVT in infants after 4 months of antiarrhythmic medication compared to retrospectively reviewed cohort.

Official Title
-----------------
Shortening Duration of Antiarrhythmic Medication for SVT in Infants

Conditions
-----------------
Supraventricular Tachycardia

Intervention / Treatment
-----------------
* Drug: Propranolol
* Drug: Flecainide
* Drug: Amiodarone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 6 months or less Documented SVT due to AVRT or AVNRT Exclusion Criteria: Age > 6 months Ectopic atrial tachycardia Atrial flutter Atrial fibrillation Permanent junctional reciprocating tachycardia

Ages Eligible for Study
-----------------
Maximum Age: 6 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Propranolol|3 mg/kg/d, divided in four doses when age less than 3 months and in three doses when age more than 3 months|
|Drug: Flecainide|80 mg/m2/d|
|Drug: Amiodarone|Single dose of 10 mg/kg/d 10-14 days, 5 mg/kg/d|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence of SVT after antiarrhythmic medication |  | 1 year follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of participants with treatment failure |  | 4 months of antiarrhythmic medication | 
| Prevalence of adverse events |  | 4 months of antiarrhythmic medication | 
| Recurrence of SVT after one year follow-up |  | 5 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tachycardia, Supraventricular, Anti-Arrhythmia Agents, Arrhythmias, Cardiac